CENTURY THERAPEUTICS INC (IPSC)
Health Care · Cell therapy and regenerative medicine; allogeneic immunotherapy · NASDAQ
Century Therapeutics is an innovative biotechnology firm developing off-the-shelf, gene-edited iPSC-derived cell therapies to cure cancer and autoimmune diseases.
What CENTURY THERAPEUTICS INC does
Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer. The company leverages proprietary CRISPR-based genetic engineering and its Allo-Evasion™ technology to create "off-the-shelf" iPSC-derived immune cells (T cells, NK cells) and beta islet cells that can be manufactured at scale and administered without patient-specific customization. Its lead programs include CNTY-101 (CAR-iNK cells in Phase 1/2 trials), CNTY-308 (CD19-targeted CAR-T cells in IND-enabling studies), and CNTY-813 (beta islet cells for type 1 diabetes in IND-enabling studies).
Themes: Cell therapy / regenerative medicine, Allogeneic cell-based immunotherapy, iPSC-derived cell therapies, CAR-T and CAR-NK cell therapies, Type 1 diabetes / beta islet cell therapy, B-cell-mediated autoimmune diseases, Off-the-shelf cell therapy, Gene editing / CRISPR
Fundamentals
- Price$2.07 as of 2026-08-21 close
- Market cap$375M as of 2026-08-21
- 1-year return+282.6% 2025-08-21 close $0.541 → 2026-08-21 close $2.07
- P/En/a negative earnings
- Net margin-18.9% as of 2026-08-24
- ROE-53.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+175.9% as of 2026-08-24
- Revenue CAGR (3y)+175.9% SEC XBRL
- Beta1.64 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How IPSC compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CENTURY THERAPEUTICS INC looks technically
CENTURY THERAPEUTICS INC (IPSC) is trading 12.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 172 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 12 trading days ago. It is 31.9% below its highest point of the past year. Trading volume is unusually light — only about 46% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 12.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +12.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.17 | $2.17 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.85 | $1.85 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 2.08. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 172 trading days ago — a "golden cross", a bullish long-term signal | 172 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 50.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($1.89 to $2.12) — its "stochastic" reading is 80 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 80.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.04 | $3.04 |
|---|---|---|
| From the 52-week high | it is 31.9% below its 52-week high (its highest price of the past year) | -31.9% |
| Above the 52-week low | it is 375.9% above its 52-week low (its lowest price of the past year) | +375.9% |
| Below the 52-week high | it is 31.9% below its highest point of the past year | 31.9% |
| Since a 20-day breakout | it made a new 20-day low about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day low about 12 trading days ago | 12 sessions |
| All-time high | its highest closing price on record is $11.95 (set on 2022-11-11) | $11.95 |
| Given back of the 52-week move | over the past year its closes ranged ($0.465 to $2.94), and it has given back roughly a third of its rise from last year’s low — 35% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.33 to $1.41. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 35.1% |
| From the all-time high | it is 82.7% below its all-time high | -82.7% |
| Nearest price level | it is trading 1.0% below a resistance level at $2.09 — a price it turned at twice since 2026-05-19, most recently on 2026-07-13. Since 2024-08-21 it has 8 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.0% |
| All-time low | its lowest closing price on record is $0.3418 (set on 2025-04-09) | $0.3418 |
| Above the all-time low | it is 505.6% above its all-time low | +505.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 89% of it) | 11th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1149 between its high and its low — about 5.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1149 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.87 and $2.15 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.87 – $2.01 – $2.15 |
| Typical daily range (% of price) | its price moves about 5.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 2.0 daily ranges above its 200-day average price (12.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 46% of its 30-day average | 0.46× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.5% |
|---|---|---|
| Gap filled | a 2.0% gap up opened on 2026-08-04 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.9 percentage points (the stock lost 7.6% while the market gained 2.3%) | -9.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 11.9 percentage points (the stock lost 8.8% while the market gained 3.1%) | -11.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 10.6 percentage points (the stock gained 0.5% while the market gained 11.1%) | -10.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 262.1 percentage points (the stock gained 282.6% while the market gained 20.5%) | +262.1% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.2% of the share price, which is taken to mean a barrier that gives way easily. | -8.6% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.16 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -4.3% |
|---|
Price levels it has turned at before
IPSC last closed at $2.07 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.09 | Resistance | 1.0% above the last close | turned there twice · 2026-05-19 to 2026-07-13 |
| $2.16 | Resistance | 4.6% above the last close | turned there twice · 2026-04-29 to 2026-06-29 |
| $1.87 | Support | 9.5% below the last close | turned there twice · 2024-09-30 to 2026-08-06 |
| $1.82 | Support | 12.1% below the last close | turned there twice · 2024-12-02 to 2026-01-21 |
| $2.41 | Resistance | 16.4% above the last close | turned there twice · 2026-04-01 to 2026-05-14 |
| $0.684 | Support | 67.0% below the last close | turned there twice · 2025-02-11 to 2025-07-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $2.08.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $2.00 and $2.08 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $1.89.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$4.75 range $2.00 – $8.00; median $4.50
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IPSC
- Consensus EPS estimate-$0.11 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Early-stage clinical development: lead program (CNTY-101) in Phase 1/2 IST; CNTY-308 and CNTY-813 still in IND-enabling studies with no guarantee of regulatory approval or successful advancement to clinical trials","Novel technology risk: iPSC-derived allogeneic cell therapies represent a novel approach with limited clinical validation; regulatory pathways are uncertain and public scrutiny of cell-based immunotherapy could impact market acceptance","Manufacturing and scaling challenges: achieving consistent reproducibility, genomic stability, and cost-effective manufacturing at commercial scale; dependence on third-party suppliers and contract manufacturers"]
What changed in the latest 10-Q
AI-assisted comparison of IPSC's 10-Q filed 2026-05-13 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- In January 2026, we entered into a securities purchase agreement with the 2026 Investors in connection with the 2026 Private Placement (newer filing, 2026-05-13)
- Cash, cash equivalents and investments as of March 31, 2026 of $217.0 million will be sufficient to fund operations into the first quarter of 2029 (newer filing, 2026-05-13)
- Investigators of the CARAMEL IST presented initial data in December 2025 (newer filing, 2026-05-13)
- Removed:
- Sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs (removed in newer filing, 2026-05-13)
- iPSC-derived gd T cells, or gd IT cells (removed in newer filing, 2026-05-13)
- iPSC-derived beta islet cells (removed in newer filing, 2026-05-13; replaced with iPSC-derived islet cells)
- In July 2025, we completed a reduction in force by approximately 51% of our workforce as part of a broader effort to right size the organization to focus on clinical execution of key programs (removed in newer filing, 2026-05-13)
- Based on our current business plans, we believe our cash, cash equivalents and investments as of September 30, 2025, will be sufficient for us to fund our operating expenses and capital expenditures requirements into the fourth quarter of 2027 (removed in newer filing, 2026-05-13)
- Reworded:
- Company description changed from 'autoimmune diseases and cancer' to 'autoimmune diseases, including type 1 diabetes, or T1D, and cancer' (newer filing, 2026-05-13)
- Program description changed from 'natural killer, or NK, T cell, and beta islet programs' to 'islet, T cell and NK cell programs' (newer filing, 2026-05-13)
- Platform capability changed from 'generate functional mature cells from iPSCs' to 'generate fully functional mature cells from iPSCs, or iPSC-derived cells' (newer filing, 2026-05-13)
- Removed 'Sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs' as separate bullet point; platform now focuses on Allo-Evasion™ technology instead (newer filing, 2026-05-13)
- Cell types description reordered: 'iPSC-derived islet cells, iPSC-derived CD4+ and CD8+ ab T cells, or ab iT cells, and iPSC-natural killer cells, or iNK cells' (newer filing, 2026-05-13) versus 'iPSC-derived natural killer cells, or iNK cells, iPSC-derived gd T cells, or gd IT cells and iPSC-derived CD4+ and CD8+ ab T cells, or ab iT cells, and iPSC-derived beta islet cells' (older filing, 2025-11-13)
- CNTY-813 description changed from 'beta islet program' to 'iPSC-derived islet program' (newer filing, 2026-05-13)
- CNTY-813 timeline changed from 'poised to move CNTY-813 into IND-enabling studies by the end of 2025. We anticipate submission of an IND as early as 2026' to 'advanced CNTY-813 into IND-enabling studies and expect to submit an IND in the fourth quarter of 2026' (newer filing, 2026-05-13)
- CARAMEL IST update changed from 'are expected to present initial data in December 2025' to 'presented initial data in December 2025' (newer filing, 2026-05-13)
- Fiscal year reference changed from 'December 31, 2024' to 'December 31, 2025' (newer filing, 2026-05-13)
- Annual Report filing date changed from 'March 19, 2025' to 'March 12, 2026' (newer filing, 2026-05-13)
- Quarterly report date changed from 'September 30, 2025' to 'March 31, 2026' (newer filing, 2026-05-13)
- cGMP facilities description changed from 'current good manufacturing practices, or cGMP, facilities' to 'clinical-scale cGMP facilities' (newer filing, 2026-05-13)
- Notes:
- The older filing text appears to be truncated at the end of the expenses bullet list; comparison of the final bulleted items may be incomplete
Risk Factors
- Added:
- Added reference to 'islet cells' in forward-looking statements about iPSC-derived cell types (filed 2026-05-13)
- Added bullet point about 'other risks and uncertainties, including those described or incorporated by reference under the caption "Risk Factors"' at end of forward-looking statements list (filed 2026-05-13)
- Removed:
- Removed 'early clinical nature' and replaced with 'early preclinical and clinical nature' (filed 2026-05-13)
- Removed specific reference to 'iPSC-derived natural killer cells, or iNK cells, iPSC-derived T cells, or iT cells, and iPSC-derived non-immune cells' and replaced with more general 'iPSC-derived immune cells and islet cells' (filed 2026-05-13)
- Removed bullet point about reliance on FUJIFILM Cellular Dynamics Inc. (FCDI) for key technology (filed 2026-05-13)
- Removed bullet point about ability to successfully manufacture certain product candidates (filed 2026-05-13)
- Removed 'and inflammatory therapies' from description of public opinion regarding cell-based therapies (filed 2026-05-13)
- Removed reference to 'trade disputes and tariffs' from macroeconomic factors list (filed 2026-05-13)
- Removed 'and' at end of final bullet point in forward-looking statements list, replaced with period (filed 2026-05-13)
- Removed duplicate paragraph about inaccuracy being material (filed 2026-05-13)
- Removed parenthetical clarification '(the "Securities Act")' and '(the "Exchange Act")' (filed 2026-05-13)
- Reworded:
- Updated Annual Report reference from 'December 31, 2024' to 'December 31, 2025' (filed 2026-05-13)
- Updated Item 1A page reference from 46 to 41 in Table of Contents (filed 2026-05-13)
- Updated multiple Item page references from 46-47 to 41-43 range (filed 2026-05-13)
- Updated Signatures page reference from 48 to 44 (filed 2026-05-13)
- Notes:
- The product candidate description was substantially simplified, removing specific cell type terminology (iNK cells, iT cells, non-immune cells) in favor of broader categories (immune cells, islet cells)
- FUJIFILM collaboration risk disclosure was removed entirely
- Manufacturing capability risk disclosure was removed entirely
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($544) — 1 selling insider
- Last 90 days0 buys · 5 sells ($11635) — 2 selling insiders
- Last 180 days0 buys · 6 sells ($12253) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IPSC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IPSC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,839,851
- Reported value $6,418,062
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IPSC had 29,815,354 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IPSC had 16.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 40.71 days to cover at the same settlement.
- Reported short interest (shares) 29,815,354
- Short interest (% of shares outstanding) 16.5%
- Prior settlement (shares) 28,381,612
- Reported change 5.05%
- Days to cover (reported) 40.71
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences / Kite Pharma (GILD)
- Juno Therapeutics (subsidiary of Celgene/Bristol Myers Squibb)
- Novartis CAR-T programs (NVS)
- Fate Therapeutics (FATE)
- Forty Seven Inc / Gilead (CD47 checkpoint)
- Vor Biopharma
- Sangamo Therapeutics (SGMO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IPSC vs…
Frequently asked questions
What does CENTURY THERAPEUTICS INC (IPSC) do?
Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer. The company leverages proprietary CRISPR-based genetic engineering and its Allo-Evasion™ technology to create "off-the-shelf" iPSC-derived immune cells (T cells, NK cells) and beta islet cells that can be manufactured at scale and administered without patient-specific customization.
What sector is CENTURY THERAPEUTICS INC (IPSC) in?
CENTURY THERAPEUTICS INC (IPSC) is classified in the Health Care sector. Its industry is Cell therapy and regenerative medicine; allogeneic immunotherapy. It trades on NASDAQ.
Who are CENTURY THERAPEUTICS INC's (IPSC) competitors?
Notable peers of CENTURY THERAPEUTICS INC (IPSC) include Gilead Sciences / Kite Pharma, Juno Therapeutics (subsidiary of Celgene/Bristol Myers Squibb), Novartis CAR-T programs, Fate Therapeutics and Forty Seven Inc / Gilead (CD47 checkpoint). This peer set is informational only — not financial advice.
Is CENTURY THERAPEUTICS INC (IPSC) overbought or oversold right now?
CENTURY THERAPEUTICS INC (IPSC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IPSC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.